NUVAXOVID 2026-27
- Product NDC
- 49281-026
- 11-digit product format
- 492810026
- Labeler code
- 49281
- Product ID
- 49281-026_7c54fe54-5938-4350-b3e9-08878951bedc
- Type
- VACCINE
- Nonproprietary name
- NVX-COV2928
- Dosage form
- INJECTION, SUSPENSION
- Route
- INTRAMUSCULAR
- Application
- BLA125817
- Marketing category
- BLA
- Marketing start
- 2026-08-27
- Substance
- NVX-COV2928
- Active strength
- 5 ug/.5mL
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- NUVAXOVID 2026-27
- Listing expiration
- 2027-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| NVX-COV2928 | 5 ug/.5mL |
Purple Book Biologic Products#
BLA, Proprietary name, Proper name table| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|
| 125817 | NUVAXOVID | COVID-19 Vaccine, Adjuvanted | 351(a) | Rx | 2026-08-01 |
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Sample | Status |
|---|
| 49281-026-50 | 49281002650 | 10 SYRINGE in 1 CARTON (49281-026-50) / .5 mL in 1 SYRINGE (49281-026-88) | 10 syringe | 2026-08-27 | 0 | Current |